Background: Anal squamous cell carcinoma (ASCC) incidence has been rising over the past decade,
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INTRODUCTION:
Over the last 15 years there has been an increase in the incidence of anal squamous cell carcinoma (ASCC), most dramatically in men who have sex with men (MSM) 1 . According to a recent multicenter cohort study, the incidence rate in HIV-positive MSM is 69 per 100,000, nearly five times the rate observed in HIV-negative MSM 2 . Current evidence indicates that ASCC incidence is unlikely to decline in the absence of novel treatment options 3 .
High-grade anal intraepithelial neoplasia (HGAIN) is believed to be the ASCC precursor [4] [5] [6] . The exact rate of progression of HGAIN to ASCC is not known but is estimated to be 8.5-13% [5] [6] [7] . Both anal and cervical cancers develop as a result of infection with oncogenic strains of human papilloma virus (HPV), most commonly HPV 16 and 18 8, 9 . To prevent progression to invasive cancer, cervical dysplasia is excised with the surrounding squamous-columnar junction (SCJ), with conization or loop electrosurgical excision (LEEP) [10] [11] [12] achieving cure rates of greater than 95% in HIV-negative females 12 .
Aggressive screening and treatment of cervical dysplasia has even resulted in a decline in HIV-positive women progressing to invasive cancer 13 . Anal dysplasia, like cervical dysplasia, is most frequently located at the SCJ, but resection of the anal SCJ results in undo morbidity including stricture, anal spasm and dyschezia 7, 14 . As a result, targeted ablation of individual lesions has become the most common management approach. Multiple techniques including: laser, electrocautery ablation (ECA), infrared coagulation (IRC), cryotherapy, or topical agents (imiquimod, tricholoracetic acid (TCA) and 5% 5-Fluoro-uracil cream) 7, [15] [16] [17] [18] [19] [20] [21] [22] [23] have been employed.
We previously showed that IRC was an effective in-office treatment in both HIV-negative and HIV-positive patients with individual lesion cure rates after the first ablation of 81% and 72%, respectively 20, 24 . We now endeavored to determine if in-office ECA of intra anal HGAIN was as safe and effective as IRC ablation in MSM 20, 24, 25 .
MATERIALS & METHODS:
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Statistical Analysis
Statistical analyses were performed with SAS (SAS Institute Inc., Cary, NC). Chi-squared tests were used to compare proportions and Student's t-tests to compare means, as appropriate. The Cox proportional hazards model was used to compute risk ratios (equivalent of odds ratios) and confidence intervals after adjusting for other covariates. Recurrence rates were estimated using Kaplan-Meier product limit method with comparison between the HIV-positive and HIV-negative groups evaluated with logrank statistic. Table 1 details the overall recurrence rates observed for HIV-negative and HIV-positive MSM.
RESULTS
HGAIN recurrence after ECA
In both the HIV-positive and HIV-negative groups, more patients recurred after first electrocautery than remained disease free. In the HIV-negative group 53 (53%) patients recurred after first ablation with a
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Comparison of HGAIN recurrence between HIV-positive and HIV-negative MSM
Our data demonstrates that HGAIN recurrence was greater among HIV-positive patients than HIV-negative patients ( Figure 2 Of note, at last visit, 83% of HIV-negative and 69% of HIV-positive patients were HGAIN free.
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Adverse events
One No patients developed other serious adverse events following ECA, including anal stenosis, persistent bleeding, hemorrhage, failure to heal, or infection necessitating antibiotic therapy. Most often pain was the only post-procedure complaint and was adequately controlled by over the counter medication or mild narcotic analgesia, however no post procedure diaries were utilized.
DISCUSSION:
This study represents the largest efficacy analysis of ECA to date. The only other major study published by Chang et al. in 2002 examines ECA for extensive HGAIN disease in the operating room setting. The study reported recurrence rates of 79% in HIV-positive group and 0% in HIV-negative group, but was limited by small size (n=37) and fairly short follow up 21 . In the extended and much larger followup series that included these patients, the 0% recurrence did not hold 22 . Our results confirm that ECA is an effective treatment for HGAIN, and can be used safely in-office.
In both HIV-positive and HIV-negative patients, lesions that failed initial ECA were less likely to be successfully ablated on subsequent treatment. This observation has both positive and negative Comparing overall recurrence rates to persistence rates clearly demonstrates that recurrence in non-treated areas (metachronous recurrence) is the major factor preventing patients from achieving disease free status. While our study demonstrates that ECA effectively ablates dysplastic lesions, it also suggests that even with successive treatments recurrence over time remains a problem. Clearly, ablation destroys dysplastic cells but does not eradicate the HPV infection from other cells or prevent re-infection leaving the patient at risk for new foci of dysplasia. It remains to be seen with long-term follow-up for patients in monogamous relationships if risk of recurrence decreases.
Despite the fact that patients required multiple treatments to ablate HGAIN and recurrence remained high, morbidity was minimal. The mean time to recurrence in both groups approached a year.
Moreover, the mean number of recurrent lesions did not exceed two so repeat ablations were localized and not extensive. This could translate into less pain with more rapid healing. (Table 3) . Of note, in the IRC study, both the HIV-negative and HIV-positive groups were younger with mean age of 38 & 41 years as compared to 42 and 49 years respectively (p<.0001, p=0.02) in this EC study. In addition, in the IRC study the mean number of lesions at first treatment in HIV-positive patients was 1.6 versus 2.2 lesions in this study (p= 0.0005). In light of previously described relationship between disease burden and recurrence in the HIV-positive patients we might expect that these differences would cause increased recurrence in the current EC trial, but this was not the case. The IRC data we reported is also consistent with 2 other studies of HIV-positive MSM that reported individual lesion cure rates of approximately 65% 14, 23 . Therefore given that IRC and ECA have similar outcomes when treating HGAIN, the choice of modality should be based on clinician comfort and preference. ECA does require smoke evacuation that is best handled with an assistant while IRC does not.
Comparison of ECA to other treatments
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It is, however, our belief that whether these minor surgical procedures are performed with IRC or ECA, an assistant should a problem could arise even in the best of circumstances. Although not measured, in our hands the overall impression was that EC seemed faster, more hemostatic and allowed more extensive disease to be treated in office than the IRC.
Topical agents for treating HGAIN have also been studied. Imiquimod was recently evaluated in a double blind randomized controlled trial 19 . In the treatment group of 28 patients, Imiquimod demonstrated a 61% cure rate over 36 months. While Imiquimod could be a promising non-surgical treatment, it required three times weekly application for four months. That withstanding the treatment was tolerable with only a few patients discontinuing treatment. TCA has also been used for topical ablation in patients with limited disease with 73% and 71% individual lesion cure rates for AIN1 and AIN2-3, respectivelyA C C E P T E D Some clinicians advocate a more conservative approach monitoring HGAIN closely and only treating if early ASCC develops or if lesions become palpable or grossly visible 29 . Their rational is that many patients with HGAIN will not progress to cancer and those that do will be caught early when lesions can be cured by excision. However, recent studies by Ortholan et al. looked at recurrence rates after treatment of T1 or T1S anal cancer, and found that excision alone for T1S had a 33% local recurrence rate requiring radiation therapy 30 . Patients with invasion into the submucosa (T1), who failed local treatment, required abdominoperineal resection. These outcomes are associated with significant morbidity and decreased quality of life. Treatment of HGAIN aims to reduce incidence of anal cancer and requirements for large surgical resection or radiation, and chemotherapy. Although unfortunate, one patient developed ASCC while managed with ECA. To date, HGAIN treatment series document a 0-1.2%
progression to ASCC which is far lower than retrospective studies which report an 8.5 to 13% progression without intervention 5-7, 20, 22, 24 . Based on these estimates the incidence of anal cancer would be predicted to be much higher in our cohort had HGAIN not been ablated.
There are several limitations to this study besides the fact that it is retrospective with a relatively short follow-up. While HRA is the gold standard in detection of HGAIN, it requires human interpretation, which allows for the possibility that lesions can be missed and recurrence under-diagnosed. In addition, patients with benign cytology and negative standard anoscopy were considered non-recurrent which might further underestimate recurrence rates. The study was performed only on males, which could limit applicability to women. Moreover, patients were excluded from in-office management if their disease was judged too extensive and these results may not be generalizable to patients with large volume HGAIN. In 
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CONCLUSION:
ECA of HGAIN is a safe and effective office based procedure comparable to other available treatments. Cure rates of individual lesions are excellent but patients continue to develop metachronous recurrence making continued follow-up important. While we documented a single progression to ASCC (0.4%), rates are far lower than series advocating a "watch and wait" approach.
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We would like to express our appreciation to the pathologists at Enzo (Farmingdale, NY) and Quest Laboratories (Teterboro, NJ) for their guidance with anatomic pathology and cytology. We also would like to thank Erin Moshier for her assistance with statistical analysis. nd time with adequate follow up. Among those 36 patients, there were 58 persistent lesions treated and followed a 2 nd time with ECA and only 12 persisted after the 2 nd ECA treatment. b) HIV-negative patients: Of the 6 patients that had a persistent lesion after 2 nd electrocautery, 4 patients were retreated with a 3 rd electrocautery treatment after which no patient was observed to have persistence. HIVpositive patients: Among the 11 HIV-positive patients who had at least 1 lesion persist after their 2 nd ECA treatment 8 had that (those) persistent lesion(s) treated a 3 rd time with ECA (and could be followed). Of those 8 patients, there were 9 persistent lesions treated and followed a 3 rd time with ECA and 5 persisted after the 3 rd ECA treatment. 
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